Table 1 Percentage of patients achieving normalization1 of C-reactive protein levels and serum amyloid A protein levels
Variable | Canakinumab 10 mg N= 28 | Canakinumab 25 mg N= 29 | Canakinumab 50 mg N= 28 | Canakinumab 90 mg N= 29 | Canakinumab 150 mg N= 27 | Triamcinolone acetonide 40 mg N= 56 |
|---|---|---|---|---|---|---|
CRP | Ā | Ā | Ā | Ā | Ā | Ā |
Baseline | 4 (14.3) | 8 (27.6) | 6 (21.4) | 6 (20.7) | 5 (18.5) | 12 (21.4) |
3 days post-dose | 6 (22.2) | 13 (46.4) | 9 (34.6) | 9 (32.1) | 11 (44.0) | 19 (35.8) |
7 days post-dose | 13 (46.4) | 21 (72.4)* | 16 (57.1) | 19 (67.9)* | 19 (70.4)* | 23 (41.8) |
4 weeks post-dose | 21 (77.8)* | 22 (78.6)* | 20 (74.1)* | 18 (64.3) | 20 (74.1)* | 27 (49.1) |
8 weeks post-dose | 17 (65.4)* | 21 (75.0)* | 17 (63.0) | 21 (75.0)* | 22 (81.5)* | 23 (42.6) |
SAA | Ā | Ā | Ā | Ā | Ā | Ā |
Baseline | 8 (28.6) | 9 (32.1) | 9 (32.1) | 8 (27.6) | 9 (33.3) | 23 (44.2) |
3 days post-dose | 15 (57.7) | 14 (50.0) | 16 (57.1) | 13 (46.4) | 13 (48.1) | 26 (48.1) |
7 days post-dose | 19 (67.9) | 22 (75.9)* | 19 (67.9) | 21 (75.0)* | 17 (65.4) | 25 (47.2) |
4 weeks post-dose | 24 (88.9)* | 24 (82.8) | 19 (70.4) | 20 (71.4) | 18 (69.2) | 34 (63.0) |
8 weeks post-dose | 18 (69.2) | 21 (80.8) | 18 (69.2) | 19 (70.4) | 20 (74.1) | 30 (57.7) |